Skip to content
Study details
Enrolling now

The Influence of Mitochondrial-Derived Reactive Oxygen Species on Racial Disparities in Neurovascular Function

Auburn University
NCT IDNCT04334135ClinicalTrials.gov data as of Apr 2026
Target enrollment

60

Study length

about 4.9 years

Ages

19–75

Locations

1 site in AL

About this study

This trial is testing whether a treatment called MitoQ can help reduce racial disparities in blood vessel function and nervous system regulation of blood pressure. The goal is to understand if mitochondrial reactive oxygen species influence blood vessel function and nervous system regulation of blood pressure differently in Black individuals compared to White individuals, potentially explaining why Black people are at higher risk for cardiovascular disease.

Based on ClinicalTrials.gov records.

What participants do

  • 1.MitoQ
DrugMitoQ
Primary goalChanges in blood pressure reactivity

Participation effort

Estimated from trial records. Details can vary by site.

Time + visits
Low13%
Logistics
Moderate50%

Logistics difficulty varies by site location and availability.

Trial highlights

Treatment details

Auto-extracted from trial records to preview treatments and outcomes.

Drug classes

dietary supplement

Endpoints

Primary: Changes in blood pressure reactivity

Secondary: Cardiorespiratory fitness, Physical activity

Body systems

Renal